Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Non-Small Cell Squamous Lung Carcinoma

Gruppo Oncologico Italiano di Ricerca ClinicaSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

52 Active assets in the Non-Small Cell Squamous Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BBB
Pembrolizumab
Shanghai Henlius Biotech
Phase 3BB
Serplulimab
Shanghai Henlius Biotech
Phase 3BB
Docetaxel
Shanghai Henlius Biotech
Phase 3BB
Tislelizumab
BeOne Medicines
Phase 3BB

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
adenocarcinomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →